These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35733414)

  • 21. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
    Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
    Singh D; van den Berg F; Leaker B; Corradi M; Jabbal S; Collarini S; Mongelli V; Santoro L; Piccinno A; Biondaro S; Lipworth B
    Br J Clin Pharmacol; 2019 Apr; 85(4):729-736. PubMed ID: 30586199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
    Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
    Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
    Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
    Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
    BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD.
    Dean J; Panainte C; Khan N; Singh D
    Respir Res; 2020 Dec; 21(1):323. PubMed ID: 33298062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.
    Dhillon S; Keating GM
    Drugs; 2006; 66(11):1475-83; discussion 1484-5. PubMed ID: 16906779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
    Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
    Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial.
    Watz H; Kirsten AM; Ludwig-Sengpiel A; Krüll M; Mroz RM; Georges G; Varoli G; Charretier R; Cortellini M; Vele A; Galkin D
    Respir Res; 2024 Oct; 25(1):378. PubMed ID: 39420338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An
    Usmani OS; Mignot B; Kendall I; Maria R; Cocconi D; Georges G; Scichilone N
    J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):204-211. PubMed ID: 33052749
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
    Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
    Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.
    Richeldi L; Piraino A; Macagno F; Micarelli G; Ingrassia E
    Int J Chron Obstruct Pulmon Dis; 2021; 16():159-166. PubMed ID: 33536751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
    O'Connor BJ; Collarini S; Poli G; Brindicci C; Spinola M; Acerbi D; Barnes PJ; Leaker B
    BMC Pulm Med; 2011 Dec; 11():60. PubMed ID: 22188731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
    Corradi M; Spinola M; Petruzzelli S; Kuna P
    Ther Adv Respir Dis; 2016 Oct; 10(5):492-502. PubMed ID: 27340255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
    Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
    J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
    Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
    Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers.
    Poli G; Acerbi D
    Respir Med; 2003 Feb; 97 Suppl B():S5-9. PubMed ID: 12593521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.